Day: April 2, 2026

HAMPTON, N.J., April 01, 2026 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (“Celldex” or the “Company”) (Nasdaq: CLDX) today announced the pricing of an underwritten public offering of 10,345,000 shares of its common stock at a public offering price of $29.00 per share. All of the shares to be sold in the offering are to be sold by Celldex. In connection with the offering, Celldex has also granted the underwriters a 30-day option to purchase up to an additional 1,551,750 shares of common stock at the public offering price, less the underwriting discounts and commissions. The Company expects to receive gross proceeds from the offering, excluding the exercise of the underwriters’ option, if any, of approximately $300 million, excluding the underwriting discounts and commissions and other offering-related expenses. The offering is...

TORONTO, April 01, 2026 (GLOBE NEWSWIRE) — Trisura Group Ltd. (“Trisura” or “Trisura Group”) (TSX: TSU), a leading specialty insurance provider, today announced the appointment of Chris Sekine to its Board of Directors and the retirement of Robert Taylor. In addition, Trisura today announced that Chris Sekine is expected to stand for election to the Board of Directors at this year’s Annual Meeting of Shareholders. Mr. Taylor served as the Chairman and a director of Trisura Guarantee Insurance Company from 2013 to 2017. As a co-founder of Trisura Guarantee Insurance Company, Mr. Taylor served as the CEO of the company from its inception in 2006 until 2012. Mr. Sekine served as President and CEO of Trisura Guarantee Insurance Company from 2018 to 2024 and has been with the Company since its inception in 2006 when he established the...

MELBOURNE, Australia and INDIANAPOLIS, April 02, 2026 (GLOBE NEWSWIRE) — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces the appointment of David Gill as a Non-Executive Director (NED), as part of Board expansion and succession planning. The appointment is effective May 11, 20261. Mr. Gill is expected to be appointed as Chair in due course, succeeding Dr. Mark Nelson who will remain on the Board as a NED. Mr. Gill is a life sciences executive with over 35 years’ experience in senior general management and financial leadership roles across commercial and clinical-stage biopharmaceutical (including radiopharmaceuticals) and medical device companies. He currently serves on the boards of Evolus, Inc. (NASDAQ: EOLS), Allucent LLC, Bridge to Life Ltd, RapidPulse Inc. and huMannity Medtec (formerly Alfred...